This “Eight-Factor Analysis” Is Not Science — It’s a Delay Tactic

Trade groups are submitting a report by Pinney Associates to regulators, calling it a neutral “Eight-Factor Analysis.” It is not.

It is an industry defense document that uses selective science, strategic table design, and semantic maneuvering to avoid the regulatory consequences of facts the authors themselves acknowledge.

The Core Fact They Admit — Then Bury

The report acknowledges that humans metabolize mitragynine into 7-hydroxymitragynine (7-OH), a substantially more potent μ-opioid receptor agonist.

Humans are never exposed to “mitragynine alone.” Every dose produces predictable exposure to a stronger opioid inside the body.

Once this fact is accepted, the report’s downstream conclusions begin to fail.

Why the Abuse-Potential Analysis Fails

• Abuse potential conclusions rely heavily on rodent studies, despite known metabolic differences between rodents and humans.
• The analysis treats those animal results as descriptive of human risk, even while acknowledging human-specific opioid metabolite formation.
• The most clinically relevant exposure pathway is therefore excluded from evaluation.

This is not conservative science. It is model selection designed to minimize the outcome.

The Factor 8 Sleight of Hand

The report claims mitragynine is not a “precursor” because it is not chemically converted to 7-OH during manufacturing.

That argument ignores biological reality. In humans, mitragynine functions as a biological precursor. The body performs the conversion.

Public-health risk does not depend on where the conversion occurs.

The Tables Are Doing the Persuasion

• Adverse events and deaths are grouped under “mitragynine,” then minimized as confounded.
• Smaller counts under “7-OH” are highlighted as the real danger.
• The tables do not explain that mitragynine detections necessarily include downstream 7-OH exposure in humans.
• The admissions about metabolism appear later and are never re-integrated into the risk analysis.

This is data framing, not neutral presentation.

They Describe the Fire — Then Recommend a Pamphlet

The report acknowledges:

• Escalating potency
• Consumer confusion and mislabeling
• An arms race in high-potency products
• Retail availability of opioid-active compounds

The proposed solution is voluntary standards and improved labeling. That approach has failed repeatedly with opioid-like substances.

This Is Not an Independent Report

The document is funded by a nonprofit created by the American Kratom Association and authored by consultants to kratom manufacturers.

That does not require dismissal — but it does require recognition of purpose.

Bottom Line for Lawmakers

This report asks regulators to ignore human metabolism, discount real-world harm, and accept incremental safeguards that have failed elsewhere.

That is not caution. That is delay.

Delay is how emerging drug problems become public-health failures.